Our viruses selectively infect and kill cancer cells, and activate anti-cancer immune responses. Our technology replicates profusely in cancer cells, with negligible effects on normal cells.
RC402
A naturally occuring reovirus originally isolated from a healthy child, which pre-clinical studies have shown to be highly effective at fighting metastatic tumors (RC402).
-
Proven to be long-lasting, safe, & stable for human subjects
-
Improved cytopathic effect without additional arming in select tumor types
-
Anti-angiogenic effect to kill tumors
-
Applicable for both local and systemic administration
-
Usage patent granted in Korea, China, & Japan
-
Clinical trial currently underway in Australia for liver-metastasized solid tumors
RP116
A naturally occuring reovirus which preliminary research has shown to be highly effective at fighting oral cancers, salivary gland cancer, soft tissue sarcoma, melanoma, etc. (RP116)
-
First-in-the-world, proprietary oncolytic virus with modification of sigma1, a major immunogenic capsid protein of RC402
-
Systemic administration with a potent tumor killing activity
-
Applicable to immuno-competent and compromised tumor patients, e.g. pregnant women, children, AIDS patients, etc.
-
Patents granted in the USA / Challenge to global market
MC509
A naturally occuring rabbit-specific poxvirus, originally isolated from a Brazillian rabbit species. Not known to cause diseases outside of rabbit species. In pre-clinical studies, MC509 has been highly oncolytic against tumor-bearing animals.
-
Engineered, multi-armed oncolytic virus
-
Systemic administration possible without generating neutralizing antibodies
-
-
Using gene editing to create new viral agents
-
Manipulation of tumor micro-environment for immune evasion, boosting, etc.
-
Creation of cancer vaccines
-
-
Targets global pharma for licensing-out & partnership
SC717
A naturally occuring squirrel-specific poxvirus originally isolated from a grey squirrel. Not known to cause diseases outside of squirrel species. In pre-clinical studies, SC717 has been highly oncolytic against tumor-bearing animals.
-
Oncolytic viral activity discovered and patented by Virocure
-
Systemic administration possible without generating neutralising antibody
-
Using gene editing to create new viral agents
-
Manipulation of tumor micro-environment for immune evasion, boosting, etc.
-
Creation of cancer vaccines
-
-
Targeting global pharma for licensing-out & partnership
Development Pipeline
Virus Platform Discovery Research Preclinical Phase I Phase II/III
RC402 Advanced malignant solid tumors
Phase I begins 2H 2019. Various options planned for completion, e.g. licensing out
RP116 Head & neck cancer, prostrate cancer
Patent registered in the United States. First target is for orphan drug designation.
MC509-XX Solid cancers
Engineered virus (currently in development). Patents registered for cancer treatment in Korea, China, & Japan.
SC717 Solid cancers
Engineered virus (currently in development). Patents registered for cancer treatment in Korea.
Combination therapies
First-in-class, patented, virus+ICI, virus+virus. Various combination therapies with ICI and other specific viruses are currently in development.
Last updated 19 Aug 2020